Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It acts as a positive allosteric modulator of the GABA-A receptor, enhancing inhibitory neurotransmission.
## Primary Indications
* Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years and older.
* Off-label uses may include other seizure disorders or anxiety, but these are not FDA-approved indications and require careful consideration of risks and benefits.
## Adult Dosing
* **Lennox-Gastaut Syndrome:** Initial dose is typically 5 mg twice daily. The dose can be increased by 2.5-5 mg/day every week. The usual maintenance dose is 10-20 mg twice daily, with a maximum recommended dose of 20 mg twice daily (40 mg/day). Dosing should be individualized.
## Pediatric Dosing
* **Lennox-Gastaut Syndrome (2 to less than 10 years of age):** Initial dose is typically 5 mg twice daily. The dose can be increased by 2.5 mg/day every week. The usual maintenance dose is 10 mg twice daily, with a maximum recommended dose of 20 mg twice daily (40 mg/day).
* **Lennox-Gastaut Syndrome (10 years of age and older):** Dosing is the same as for adults.
* **Note:** Dosing for pediatric patients should be individualized based on weight and clinical response.
## Dose Adjustments
* **Hepatic Impairment:** Clobazam is metabolized in the liver; caution and potentially reduced doses are advised in patients with hepatic impairment. Specific dosing recommendations are not well-established.
* **Renal Impairment:** No specific dose adjustments are recommended for mild to moderate renal impairment, but caution is advised.
## Contraindications
* Hypersensitivity to clobazam or other benzodiazepines.
## Adverse Effects
* **Common:** Somnolence, decreased appetite, constipation, fatigue, aggression, irritability, respiratory infections.
* **Serious:** Severe dermatologic reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), suicidal behavior or ideation, withdrawal symptoms (if abruptly discontinued), CNS depression, dependence and abuse potential.
## Key Drug Interactions
* **CNS Depressants:** Additive CNS depression with alcohol, opioids, other benzodiazepines, sedatives, hypnotics, and certain antidepressants.
* **CYP2C19 Substrates:** Clobazam is a moderate inhibitor of CYP2C19. This can increase the concentration of drugs metabolized by CYP2C19 (e.g., citalopram, esomeprazole, omeprazole, phenytoin, diazepam). Monitor for increased toxicity of these agents.
* **CYP3A4 Substrates:** Clobazam can induce CYP3A4, potentially decreasing the efficacy of drugs metabolized by this enzyme.
## Monitoring
* Monitor for signs of sedation, dizziness, and impaired coordination, especially during initiation or dose increases.
* Assess for efficacy in seizure control.
* Monitor for behavioral changes, including suicidal ideation or behavior.
* Observe for signs of withdrawal if discontinuation is planned.
* Monitor for potential drug interactions, particularly with CYP2C19 substrates.
## Clinical Pearls
* Clobazam should be initiated at a low dose and titrated slowly to minimize adverse effects, particularly somnolence and behavioral changes.
* Withdrawal symptoms can occur upon abrupt discontinuation. Gradual tapering is recommended.
* Due to the risk of severe dermatologic reactions, patients should be educated to discontinue clobazam and seek immediate medical attention if a rash develops.
* Clobazam is a Schedule IV controlled substance.
***
*This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the current prescribing information and a qualified healthcare provider for any health concerns or before making any treatment decisions.*
